PharmAbcine   Report issue

For profit Phase 1 Phase 2
Founded: Daejeon Korea, Republic of (2008)

Organization Overview

First Clinical Trial
2011
NCT01660360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Head of R&D Center of PharmAbcine | PharmAbcine

Active Ingredients

Drugs in Phase 2 Trials (2)

tanibirumab (3 trials)

ttac-0001 (3 trials)

Drugs in Phase 1 Trials (1)

pembrolizumab (keytruda) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Second Primary (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3